Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients

Sun Yat-sen University1 site in 1 country597 target enrollmentJanuary 1, 2023

ConditionsBreast Cancer

Interventionscyclophosphamide , methotrexate , vinorelbine ,capecitabine

Drugscyclophosphamide , methotrexate , vinorelbine ,capecitabine

Overview

Phase: Not Applicable
Intervention: cyclophosphamide , methotrexate , vinorelbine ,capecitabine
Conditions: Breast Cancer
Sponsor: Sun Yat-sen University
Enrollment: 597
Locations: 1
Primary Endpoint: Progression free survival
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The goal of this observational study is to learn about the effects of metronomic chemotherapy in advanced breast cancer patients. The main question it aims to answer is:

How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups of metronomic chemotherapy.

Registry

clinicaltrials.gov

Start Date

January 1, 2023

End Date

January 1, 2024

Last Updated

2 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Sun Yat-sen University

Responsible Party

Principal Investigator

wang shusen

Sun Yat-sen University

Eligibility Criteria

Inclusion Criteria

•Females, \>18 years old;
•Diagnosed with advanced breast cancer when using metronomic chemotherapy;
•At least one clinical evaluation, including physical examination and imaging, according to the instructions of the supervising physician during the use of metronomic chemotherapy. Examinations include ultrasound, computed tomography, and magnetic resonance imaging;
•Metronomic chemotherapy can be used alone, and patients who use it in combination with other drugs can also be included;
•The clinical pathological information that needs to be collected is complete.

Exclusion Criteria

•Taking the drug for less than 2 weeks;
•losing follow-up after taking the therapy;
•The patient's breast cancer was still in the early stage when taking the therapy.